Brief Article
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 7, 2014; 20(1): 264-273
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.264
Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma
Ming-Ming He, Dong-Sheng Zhang, Feng Wang, Zhi-Qiang Wang, Hui-Yan Luo, Chao Ren, Ying Jin, Dong-Liang Chen, Rui-Hua Xu
Ming-Ming He, Dong-Sheng Zhang, Feng Wang, Zhi-Qiang Wang, Hui-Yan Luo, Chao Ren, Ying Jin, Dong-Liang Chen, Rui-Hua Xu, State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Author contributions: He MM and Zhang DS contributed equally to this work; He MM, Zhang DS and Xu RH designed the research; He MM, Zhang DS, Wang F, Wang ZQ and Luo HY performed the research; Ren C and Jin Y contributed new reagents/analytic tools; He MM, Zhang DS and Chen DL analyzed the data; He MM, Zhang DS and Wang F wrote the paper.
Supported by National High Technology Research and Development Program of China (863 Program), China, No. 2012AA02A506; Science and Technology Department of Guangdong Province, China, No. 2012B031800088; and Medical Scientific Research Foundation of Guangdong Province, China, No. C2011019
Correspondence to: Rui-Hua Xu, MD, PhD, Professor, Vice-President, State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, No. 651, Dongfeng East Road, Guangzhou 510060, Guangdong Province, China. xurh@sysucc.org.cn
Telephone: +86-20-87343228 Fax: +86-20-87343392.
Received: October 2, 2013
Revised: November 2, 2013
Accepted: November 18, 2013
Published online: January 7, 2014
Core Tip

Core tip: Patients after D2 gastrectomy for stage II/III gastric adenocarcinoma had a significant survival benefit after adjuvant chemotherapy compared with surgery alone, which was maintained when restricted to stage II, III or IIIB/IIIC patients. The survival did not differ significantly between the patients with p53(+) and p53(-) tumors, or between patients with carcinoembryonic antigen (CEA)(+) and CEA(-) tumors, which were maintained when the analyses were restricted to surgery alone, adjuvant chemotherapy and even different chemotherapy regimens. p53 and CEA immunohistochemical expression is not prognostic for survival after D2 gastrectomy.